Somaxon Sues Zydus Over Generic Silenor

Law360, Washington (June 16, 2011, 7:01 PM EDT) -- Somaxon Pharmaceuticals Inc. continued its campaign to protect its insomnia drug Silenor on Thursday by lodging a patent infringement suit in Delaware against Zydus Pharmaceuticals USA Inc.

The suit stems from an abbreviated new drug application Zydus filed seeking U.S. Food and Drug Administration approval to market generic versions of the 3-milligram and 6-milligram forms of Silenor, according to Somaxon. Silenor is a low-dose oral tablet formulation of the chemical doxepin, approved by the FDA for the treatment of insomnia.

Co-plaintiff ProCom One Inc. owns U.S....
To view the full article, register now.